Boehringer Ingelheim Ulm University Biocentre

An open dialogue between the university and industry eases the transfer of research results from clinical basic research into industrial development and clinical application. BIU has a total of four research profiles that work with neuropsychiatric and cardiometabolic diseases.

For example, molecular and cellular changes related to obesity and diabetes are being investigated. Other key topics include regulatory processes in inflammatory diseases, the characterisation of the involved cells and the analysis of changes in the lung epithelium in the context of diseases.

The research association pursues two goals. One is the characterisation and analysis of signal transduction pathways and their dysregulation. The second, identification and characterisation of new biomarkers required for innovative clinical studies. The focus is mainly on early preclinical analyses.

The joint projects, carried out by Boehringer Ingelheim and the researchers at Ulm University, offer both partners access to developments in basic clinical research as well as in the development of new therapeutic interventions.